The potential of anti-IL-6 therapy has previously been demonstrated in a variety of conditions, including systemic lupus erythematosus and Crohn’s disease (reviewed by Nepom et al [57]) and a clinical trial testing anti-IL6 therapy in type 1 diabetes has begun (ClinicalTrials.gov registration no. NCT02293837) [58]. The gene discussed is IL6; the disease is type 1 diabetes mellitus.